Cladribine tablets after treatment with natalizumab (CLADRINA) - rationale and design

DISCUSSION: The CLADRINA trial will generate data regarding the safety, efficacy, and immunological impact of the transition from natalizumab to cladribine. As the pace of immunological knowledge of MS continues, insight into disease modifying therapy transition strategies is needed.PMID:38585373 | PMC:PMC10996356 | DOI:10.1177/17562864241233858

Source: Adv Data - April 8, 2024 Category: Epidemiology Authors: Peter V Sguigna Rehana Z Hussain Annette Okai Kyle M Blackburn Lauren Tardo Mariam Madinawala Julie Korich Lori A Lebson Jeffrey Kaplan Amber Salter Navid Manouchehri Olaf Stuve Source Type: research